Chromatin; Nucleal metabolism; Leukemia; MDS; Drug Targets; Histone variants.
Posting about the lab and the wider scientific community.
More info about us here: www.buschbecklab.org
A ketogenic diet, enforcing lipid oxidation and lowering NAD⁺ demand, normalized RER, glucose tolerance, and liver gene profiles, completely preventing kidney abnormalities. Thus, diet overrode the metabolic phenotype associated with macroH2A1.1 loss.
A ketogenic diet, enforcing lipid oxidation and lowering NAD⁺ demand, normalized RER, glucose tolerance, and liver gene profiles, completely preventing kidney abnormalities. Thus, diet overrode the metabolic phenotype associated with macroH2A1.1 loss.
This was secondary to a systemic shift in metabolism. Respiratory exchange measurements (RER) indicated reduced oxidation of lipids and increased glucose utilization — consistent with a Warburg-like shift. This was accompanied by alterations in NAD+ metabolism.
This was secondary to a systemic shift in metabolism. Respiratory exchange measurements (RER) indicated reduced oxidation of lipids and increased glucose utilization — consistent with a Warburg-like shift. This was accompanied by alterations in NAD+ metabolism.
Mice lacking macroH2A1.1—but not macroH2A1.2 or macroH2A2—developed inflammatory lesions and hyaline casts in kidneys of both sexes, independent of local transcriptomic changes, implicating systemic rather than renal-intrinsic dysfunction.
Mice lacking macroH2A1.1—but not macroH2A1.2 or macroH2A2—developed inflammatory lesions and hyaline casts in kidneys of both sexes, independent of local transcriptomic changes, implicating systemic rather than renal-intrinsic dysfunction.
Out in Science Advances: We have dissected the physiological role of all macroH2A histone variants. In mice, loss of macroH2A1.1 specifically results in profound metabolic reprogramming and kidney pathology.
DOI: 10.1126/sciadv.adz1242
Thread 1/7
Out in Science Advances: We have dissected the physiological role of all macroH2A histone variants. In mice, loss of macroH2A1.1 specifically results in profound metabolic reprogramming and kidney pathology.
DOI: 10.1126/sciadv.adz1242
Thread 1/7
This week our postdoc René Winkler will attend the @febspress.bsky.social workshop 'Molecular and cellular pathways of aging in hematopoiesis' on Crete, Greece.
René will present work led by @shubhra.bsky.social on how cohesin mutations impact MDS progression.
This week our postdoc René Winkler will attend the @febspress.bsky.social workshop 'Molecular and cellular pathways of aging in hematopoiesis' on Crete, Greece.
René will present work led by @shubhra.bsky.social on how cohesin mutations impact MDS progression.
Today Marina Farkas is attending the "Molecular Haemopoiesis" meeting at the Francis Crick Institute in London, UK.
A gathering of researchers studying #blood development, with a particular focus on blood stem cell biology, gene regulation and #leukaemia.
Today Marina Farkas is attending the "Molecular Haemopoiesis" meeting at the Francis Crick Institute in London, UK.
A gathering of researchers studying #blood development, with a particular focus on blood stem cell biology, gene regulation and #leukaemia.
We welcome Bedri Batuhan Yaman to the group. Bedri will study the role of nuclear metabolism in #AML. He is co-supervised by @florherbstein.bsky.social and fellow of the MSCA @nucleardn.bsky.social.
Bedri is alumnus of @viblifesciences.bsky.social (Belgium) and NeuroBM (Turkey).
We welcome Bedri Batuhan Yaman to the group. Bedri will study the role of nuclear metabolism in #AML. He is co-supervised by @florherbstein.bsky.social and fellow of the MSCA @nucleardn.bsky.social.
Bedri is alumnus of @viblifesciences.bsky.social (Belgium) and NeuroBM (Turkey).
After 6 month of Master research, Francesco B. Ciriscioli is returning to his home university in Triest, Italy.
Thank you, Francesco, for your interesting results and for having enriched our group with your kind personality. We wish you all the best!
After 6 month of Master research, Francesco B. Ciriscioli is returning to his home university in Triest, Italy.
Thank you, Francesco, for your interesting results and for having enriched our group with your kind personality. We wish you all the best!
During the next 3 days, I am in northern Norway at the kick-off workshop of the HubMOL consortium. This MSCA doctoral network coordinated by Ines Heiland, University of Tromsø, aims to gain a better understanding of the dual role of NAD, CoA and co. in metabolism and signalling.
During the next 3 days, I am in northern Norway at the kick-off workshop of the HubMOL consortium. This MSCA doctoral network coordinated by Ines Heiland, University of Tromsø, aims to gain a better understanding of the dual role of NAD, CoA and co. in metabolism and signalling.
Congratulations to Lejuan Shi from Sonia Forcales' lab who has defended her thesis today.
As chair of her defense committee with Concepcio Soler and @tanyavavouri.bsky.social, I had the opportunity to discuss with Lejuan about the role of lncRNAs in cancer.
Congratulations to Lejuan Shi from Sonia Forcales' lab who has defended her thesis today.
As chair of her defense committee with Concepcio Soler and @tanyavavouri.bsky.social, I had the opportunity to discuss with Lejuan about the role of lncRNAs in cancer.
We welcome @florherbstein.bsky.social who is joining us as a @carrerasleaders.bsky.social Postdoctoral Fellow. She is alumni of #IBioBA-MPSP and the University of Buenos Aires.
She will study how nuclear metabolism influences proliferation and therapy resistance in AML.
We welcome @florherbstein.bsky.social who is joining us as a @carrerasleaders.bsky.social Postdoctoral Fellow. She is alumni of #IBioBA-MPSP and the University of Buenos Aires.
She will study how nuclear metabolism influences proliferation and therapy resistance in AML.
Our 2022 technician trainee Julia Ledesma is back. Julia is using the summer break of her biology studies at the University of Barcelona to help us advancing our projects as auxiliary technician. Thanks a lot, Julia.
Our 2022 technician trainee Julia Ledesma is back. Julia is using the summer break of her biology studies at the University of Barcelona to help us advancing our projects as auxiliary technician. Thanks a lot, Julia.
René Winkler and Marcus Buschbeck will attend #EHA2025 congress in Milan.
Find us at:
JUN 12 - Mol Hemato workshop, Brown 3
JUN 13 - EHA-ISEH Joint Symposium, Amber 7
JUN 14 - YoungEHA, Brown Hall 2 + Poster 1606
JUN 15 - Myeloid Neoplasia, Brown 1
René Winkler and Marcus Buschbeck will attend #EHA2025 congress in Milan.
Find us at:
JUN 12 - Mol Hemato workshop, Brown 3
JUN 13 - EHA-ISEH Joint Symposium, Amber 7
JUN 14 - YoungEHA, Brown Hall 2 + Poster 1606
JUN 15 - Myeloid Neoplasia, Brown 1
Did you know that we have also one project in Ewing's Sarcoma?
IF
✅ you share this interest,
✅ you are at #EUSARC2025 in Venice,
THEN
👉 reach out to Jonathan and learn more about what we do.
Did you know that we have also one project in Ewing's Sarcoma?
IF
✅ you share this interest,
✅ you are at #EUSARC2025 in Venice,
THEN
👉 reach out to Jonathan and learn more about what we do.
It was great to learn about the latest in NAD metabolism. Looking foward to more interactions through the MSCA networks @nucleardn.bsky.social and HubMOL.
It was great to learn about the latest in NAD metabolism. Looking foward to more interactions through the MSCA networks @nucleardn.bsky.social and HubMOL.
During the next three days I will be at the Universities of Oslo and Bergen in Norway.
Thanks a lot to Lorena Arranz, @ragnhildes.bsky.social and MathiasZiegler for hosting me.
During the next three days I will be at the Universities of Oslo and Bergen in Norway.
Thanks a lot to Lorena Arranz, @ragnhildes.bsky.social and MathiasZiegler for hosting me.
Today half of the lab is at the @scb.iec.cat attending the 15th Chromatin and Epigenetics Day. Kudos to Albert Jordan for organizing.
This is a fixed event in the lab's calender. In the pic below Ollie is presenting his results.
Today half of the lab is at the @scb.iec.cat attending the 15th Chromatin and Epigenetics Day. Kudos to Albert Jordan for organizing.
This is a fixed event in the lab's calender. In the pic below Ollie is presenting his results.
Sonia Nuñez, Marcus and our colleague Tanya Vavouri travelled to beautiful but rainy Bergen to interview the top-ranked candidates for the MSCA doctoral network HubMOL at UiB.
Congratulations to all candidates for great presentations and good luck!
Sonia Nuñez, Marcus and our colleague Tanya Vavouri travelled to beautiful but rainy Bergen to interview the top-ranked candidates for the MSCA doctoral network HubMOL at UiB.
Congratulations to all candidates for great presentations and good luck!
In between interviews for incoming Phd students, Jonathan, Ollie and Paula found time to run the 2025 Health Professionals Race, starting and ending in front of our door in the Can Ruti mountains. They got amazing times in this 10 K / 50% uphill circuit. Well done!
In between interviews for incoming Phd students, Jonathan, Ollie and Paula found time to run the 2025 Health Professionals Race, starting and ending in front of our door in the Can Ruti mountains. They got amazing times in this 10 K / 50% uphill circuit. Well done!
We welcome Francesco B. Ciriscioli to the team.
He is Alumnus of University of Urbino and Master student of the University of Triest. Under the supervision of Ollie Meers, Francesco will study the role of the forgotten domain of the histone variant macroH2A in genome regulation .
We welcome Francesco B. Ciriscioli to the team.
He is Alumnus of University of Urbino and Master student of the University of Triest. Under the supervision of Ollie Meers, Francesco will study the role of the forgotten domain of the histone variant macroH2A in genome regulation .
1 invited lecture
1 selected short talk
1 chair
3 flash talks and
lots of posters.
Presenting news on cohesin, HDACs, TFs, histone variants, RNA modifications and drug targets in blood cancers.
1 invited lecture
1 selected short talk
1 chair
3 flash talks and
lots of posters.
Presenting news on cohesin, HDACs, TFs, histone variants, RNA modifications and drug targets in blood cancers.